Ventipulmin® Syrup
Equine Respiratory Relief

Description
Ventipulmin® Syrup is a colorless, palatable syrup. Clenbuterol (4-amino-alpha-[(tert-butylamino)methyl]-3,5-dichlorobenzyl alcohol hydrochloride), a beta-2-adrenergic agonist, provides bronchodilating properties with minimum effect on the cardiovascular system.

Features
Only FDA-approved solution for reversible respiratory problems.
Treat-to-effect dose schedule provides optimum level of treatment.
Duration of effect from 6 to 8 hours.
Colorless, palatable syrup provides for easy oral administration.

Benefits
Relieves reversible bronchospasm arising from a variety of respiratory conditions.
Increases mucous secretions for improved airway resistance.
Improves mucociliary transport by decreasing thickness of mucous.

Advantages
Only FDA-approved treatment to relieve reversible bronchospasm from respiratory conditions such as allergy induced respiratory distress, small airway disease or chronic obstructive pulmonary disease (COPD).

Dosage & Administration
Remove safety cap and seal; replace with enclosed dispensing cap. Connect syringe (without needle) to dispensing tip and draw out appropriate volume of Ventipulmin® Syrup (clenbuterol hydrochloride). Administer to horse orally twice a day (b.i.d.). Initial dose is 0.5 mL/100 lbs body weight (0.8 mcg/kg) twice daily. See package insert for complete dosage schedule. Recommended duration of treatment at effective dose is 30 days. At end of 30-day treatment period, drug should be withdrawn to determine recurrence of signs. If signs return, repeat 30-day treatment regimen.

Precautions
Store at controlled room temperature (15-30°C) 59-86°F. Avoid freezing. The safety cap should be placed on the bottle when not in use. Ventipulmin Syrup should not be used in pregnant mares near term or in horses suspected of having cardiovascular impairment.

Uses
Ventipulmin Syrup (clenbuterol hydrochloride) is indicated for management of horses affected with airway obstruction, such as chronic obstructive pulmonary disease (COPD).

Warning
This product is not for human use or for use in animals intended for food. Federal (U.S.A.) law prohibits extralabel use of this drug in food animals. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. The reproduction effect in breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than initial dose is not recommended. Keep out of reach of children. In case of accidental ingestion, contact a physician immediately. Clenbuterol, like other beta adrenergic agonists, can produce significant cardiovascular effects in some people as evidenced by elevated pulse rate, blood pressure changes and/or ECG changes.

Product Information

<table>
<thead>
<tr>
<th>Name</th>
<th>Code</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventipulmin®</td>
<td>301-715</td>
<td>100 mL</td>
</tr>
<tr>
<td>Syrup</td>
<td>301-725</td>
<td>330 mL</td>
</tr>
</tbody>
</table>
VENTIPULMIN® Syrup
(clenbuterol HCl)

For use in horses not intended for food
Each mL contains CLENBUTEROL HCL 72.5 mcg

Caution: Federal (U.S.A.) law restricts this drug to use by or on the order of a veterinarian.
Federal (U.S.A.) law prohibits the extra-label use of this drug in food animals.

Description: CLENBUTEROL (4-amino-alpha-[(tert-butylamino)methyl]-3, 5-dichlorobenzyl alcohol hydrochloride) is a beta-2-adrenergic agonist which provides bronchodilating properties as well as other effects, with minimum effect on the cardiovascular system. It is provided as a colorless, palatable syrup. VENTIPULMIN Syrup (clenbuterol hydrochloride) is antagonized by beta-adrenergic blocking agents.

Indications: VENTIPULMIN Syrup (clenbuterol hydrochloride) is indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).

Contraindications: VENTIPULMIN Syrup antagonizes the effects of prostaglandin F2 alpha and oxytocin. VENTIPULMIN Syrup should not be used in pregnant mares near term. Because tachycardia may occur, VENTIPULMIN Syrup should not be used in horses suspected of having cardiovascular impairment.

Warning: The effect on reproduction in breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended.

Human Warnings: This product is not for human use or for use in animals intended for food. Keep out of the reach of children. In case of accidental ingestion, contact a physician immediately. Ingestion of VENTIPULMIN Syrup may cause undesirable reactions. CLENBUTEROL, like other beta adrenergic agonists, can produce significant cardio-vascular effects in some people as evidenced by elevated pulse rate, blood pressure changes and/or ECG changes.

Dosage and Administration: Administer orally twice a day (b.i.d.).

Initial dosage is 0.5 mL/100 lbs body weight (0.8 mcg/kg) twice daily.

Dosage Schedule:
Initial dosage: administer 0.5 mL/100 lbs (0.8 mcg/kg) for 3 days
If no improvement, administer 1.0 mL/100 lbs (1.6 mcg/kg) for 3 days
If no improvement, administer 1.5 mL/100 lbs (2.4 mcg/kg) for 3 days

Recommended duration of treatment at effective dose is 30 days. At the end of this 30-day treatment period, drug should be withdrawn to determine recurrence of signs. If signs return, the 30-day treatment regimen may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated.

Dosage Calculation Chart

<table>
<thead>
<tr>
<th>Lbs. Body Weight</th>
<th>mL/treatment at 0.5 mL/100# (0.8 mcg/kg)</th>
<th>mL/treatment at 1.0 mL/100# (1.6 mcg/kg)</th>
<th>mL/treatment at 1.5 mL/100# (2.4 mcg/kg)</th>
<th>mL/treatment at 2.0 mL/100# (3.2 mcg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>500</td>
<td>2.5</td>
<td>5.0</td>
<td>7.5</td>
<td>10.0</td>
</tr>
<tr>
<td>600</td>
<td>3.0</td>
<td>6.0</td>
<td>9.0</td>
<td>12.0</td>
</tr>
<tr>
<td>700</td>
<td>3.5</td>
<td>7.0</td>
<td>10.5</td>
<td>14.0</td>
</tr>
<tr>
<td>800</td>
<td>4.0</td>
<td>8.0</td>
<td>12.0</td>
<td>16.0</td>
</tr>
<tr>
<td>900</td>
<td>4.5</td>
<td>9.0</td>
<td>13.5</td>
<td>18.0</td>
</tr>
<tr>
<td>1000</td>
<td>5.0</td>
<td>10.0</td>
<td>15.0</td>
<td>20.0</td>
</tr>
<tr>
<td>1100</td>
<td>5.5</td>
<td>11.0</td>
<td>16.5</td>
<td>22.0</td>
</tr>
<tr>
<td>1200</td>
<td>6.0</td>
<td>12.0</td>
<td>18.0</td>
<td>24.0</td>
</tr>
<tr>
<td>1300</td>
<td>6.5</td>
<td>13.0</td>
<td>19.5</td>
<td>26.0</td>
</tr>
<tr>
<td>1400</td>
<td>7.0</td>
<td>14.0</td>
<td>21.0</td>
<td>28.0</td>
</tr>
<tr>
<td>1500</td>
<td>7.5</td>
<td>15.0</td>
<td>22.5</td>
<td>30.0</td>
</tr>
<tr>
<td>1600</td>
<td>8.0</td>
<td>16.0</td>
<td>24.0</td>
<td>32.0</td>
</tr>
<tr>
<td>1700</td>
<td>8.5</td>
<td>17.0</td>
<td>25.5</td>
<td>34.0</td>
</tr>
<tr>
<td>1800</td>
<td>9.0</td>
<td>18.0</td>
<td>27.0</td>
<td>36.0</td>
</tr>
</tbody>
</table>

Administer two treatments per day.

Directions for Administration: Remove safety cap and seal; replace with enclosed plastic dispensing cap. Remove cover from dispensing tip and connect syringe (without needle). Draw out appropriate volume of VENTIPULMIN Syrup. Administer orally to the horse. Replace cover on dispensing tip to prevent leakage.

Precaution: The safety cap should be placed on the bottle when not in use.

Adverse Reactions: Mild sweating, muscle tremor, restlessness, urticaria and tachycardia may be observed in some horses during the first few days of treatment. May cause elevated creatine kinase (CK) serum levels. Ataxia was observed in 3 out of 239 horses (1.3%) in clinical studies.

How Supplied: VENTIPULMIN Syrup is available in 100 mL and 330 mL plastic bottles containing 72.5 mcg clenbuterol HCl per mL.


3017011-00-9803

Boehringer Ingelheim Vetmedica, Inc.
2621 North Belt Highway • St. Joseph, MO 64506-2002
Information 800-325-9167 • Sales Service 800-325-9167 • Fax 816-236-2717
http://www.boehringer-ingelheim.com